Loading clinical trials...

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 2NCT03646968

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study

The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squa...

Lead sponsor: Yongchang Zhang•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Yongchang Zhang, MD

CONTACT

+8613873123436 yangnong0217@163.com

Yongchang Zhang, MD

CONTACT

+8613873123436 zhangyongchang@csu.edu.cn

Related studies

Not Yet RecruitingPhase 2

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

NCT06028633 · Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, and more

TERMINATEDPhase 2

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

NCT02087241 · Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 27, 2023Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment43

Start dateAug 2018

Last updatedDec 27, 2023

Condition

Non-Squamous Non Small Cell Lung Cancer

Locations shown

Hunan Cancer Hospital

Changsha, Hunan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 27, 2023Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions